Stay updated with breaking news from Nasdaq cocp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 800 shares, a decline of 20.0% from the December 31st total of 1,000 shares. Approximately 0.0% of the company’s stock are sold short. Based on an […] ....
Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,000 shares, a decline of 63.0% from the December 15th total of 2,700 shares. Approximately 0.0% of the shares of the company are […] ....
Cocrystal Pharma (NASDAQ:COCP – Free Report) had its price target decreased by HC Wainwright from $12.00 to $10.00 in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2023 earnings at ($0.58) EPS, FY2023 earnings at ($2.01) […] ....
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Volatility and Risk Cocrystal Pharma has a […] ....
HC Wainwright restated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2023 earnings at ($0.59) EPS, FY2023 earnings at ($2.03) EPS, Q1 2024 […] ....